| Literature DB >> 23478348 |
Abstract
With the declining cost of sequencing and the ongoing discovery of disease genes, it is now possible to examine hundreds of genes in a single disease-targeted test. Although exome- and genome-sequencing approaches are beginning to compete, disease-targeted testing retains certain advantages and still holds a firm place in the diagnostic evaluation. Here I examine the current state of clinical disease-targeted sequencing and evaluate the benefits and challenges of incorporating sequencing tests into patient care.Entities:
Mesh:
Year: 2013 PMID: 23478348 PMCID: PMC3786217 DOI: 10.1038/nrg3463
Source DB: PubMed Journal: Nat Rev Genet ISSN: 1471-0056 Impact factor: 53.242